Cardiovascular diseases account for the majority of deaths globally and are a significant drain on economic resources. Although heart transplants and left-ventricle assist devices are the solution for some, the best chance for many patients who suffer because of a myocardial infarction, heart failure, or a congenital heart disease may be cell-based regenerative therapies. Such therapies can be divided into two categories: the application of a cell suspension and the implantation of an in vitro engineered tissue construct to the damaged area of the heart. Both strategies have their advantages and challenges, and in this review, we discuss the current state of the art in myocardial regeneration, the challenges to success, and the future direction of the field. STEM CELLS TRANSLATIONAL MEDICINE 2016;5:410-416 
INTRODUCTION
Cardiovascular disease (CVD) remains a leading cause of death globally and a major health-care burden [1] . Myocardial infarction (MI) is a major cause of CVD death. MI results from insufficient blood supply to the heart muscle and can cause the death of 1 billion cells on average [2] . The heart is capable of limited endogenous regeneration [3, 4] , but it is insufficient to repopulate the myocardium with cardiomyocytes (CMs) postinjury. Consequently, the ventricle undergoes pathological remodeling (i.e., wall thinning and chamber dilatation), which reduces contractile function and often results in heart failure.
The application of biomaterials alone to the myocardium can reduce adverse post-MI remodeling [5] , but it is not a long-term regenerative solution because the millions of lost cells are not replaced. Hence, it is generally agreed that to restore contractile function, CMs need to be applied to the ventricle [6] .
In this review, we outline the sources of CMs available for cardiac regenerative therapy approaches; the advantages and disadvantages of the two primary regenerative strategies, direct cardiac cell injection and cardiac patch implantation (Table 1) ; and the challenges to the field and its direction moving forward.
Cardiomyocyte Sources
Human CMs are a limited resource. Adult CMs are considered terminally differentiated and proliferate minimally [3, 4] ; they also cannot be cultured indefinitely. As such, adult CMs cannot be expanded to sufficient numbers from cardiac biopsy specimens, and this has motivated the investigation into alternative CM sources. A variety of cell types have been studied, including various adult stem cells and progenitors [7] .
One strategy aimed at promoting endogenous cell proliferation involves modulating posttranslational regulation. MicroRNAs (miRNAs) are short, single-stranded, noncoding RNAs that bind and inhibit the translation of target messenger RNAs. In recent years, miRNAs have been identified that promote endogenous adult CM [8] and cardiac progenitor cell (CPC) [9] proliferation. Moreover, these miRNAs were shown to reduce infarct size and improve cardiac function in a mouse MI model [8] . Conversely, other miRNAs, such as the miR-15 family, have been identified to promote cell cycle withdrawal [10, 11] . As such, inhibitors of this category of miRNA, such as small hairpin RNA, have been proposed as a means of increasing the number of mitotic CMs [12] , and it has been demonstrated that inhibiting the miR-15 family can reduce infarct size and cardiac remodeling, and improve cardiac function in a mouse MI model [11] .
Endogenous CPCs have also been investigated as an alternative therapeutic cardiac cell source. Cardiosphere-derived cells (CDCs), obtained from primary adult heart cultures, are heart-derived multipotent stem cells [13] thought to function primarily through indirect mechanisms [14] . CDCs have been used clinically in the phase I study CADUCEUS (Cardiosphere-Derived Autologous Stem Cells to Reverse Ventricular Dysfunction), wherein patients injected with autologous CDCs 1.5-3 months post-MI had decreased scar size and increased viable myocardium (i.e., regeneration); however, no global functional improvements were observed [15] .
Recently, the focus has shifted to human-induced pluripotent stem cells (hiPSCs). Human iPSCs are biologically similar to human embryonic stem cells (hESCs), the archetype for pluripotency, but sidestep the ethical and political issues surrounding human embryo use [16] . Furthermore, hiPSCs robustly differentiate into patientspecific [17] , bona fide CMs [18, 19] , which suggests unlimited numbers of autologous CMs can be produced for cell therapy, and treatment can be provided without immunosuppression.
Initially, iPSCs were generated using retroviral transduction [20] . Although effective, this approach risked oncogenic transformation due to the random insertion of the reprogramming factors. Safer, nonintegrating methods have since been developed (e.g., Sendai virus, mRNA or miRNA, and direct protein delivery) [16] . Research is also ongoing to determine if "naïve" hiPSCs (an earlier pluripotency state than the conventional "primed" hiPSCs [21] ) may be more amenable to genomic modifications [22] and/ or differentiation into somatic tissues [23, 24] .
The most efficient cardiac differentiation protocols replicate lineage commitment pathways [18] . Current protocols have high efficiencies capable of generating highly-enriched CM populations. Early work involved applying stage-specific growth factors to embryoid bodies [25] [26] [27] [28] . Monolayer-based protocols followed, using activin A and bone morphogenetic protein 4 [29, 30] ; and, most recently, growth factor proteins were replaced by small molecules [31] .
However, the resultant hPSC-CMs obtained from these protocols are more akin to human fetal CMs, based on gene expression [32] , electrophysiology [33] , and morphology [34] than adult CMs. Currently, it is not known what the implications, as they pertain to cardiac regenerative therapy, may be that hPSC-CMs are smaller, less electrically excitable [35, 36] , have a lower sensitivity to adrenergic stimulation [37, 38] , and have impaired excitationcontraction coupling [39, 40] relative to adult CMs. Although it would be presumed that more mature CMs would provide a functional advantage upon injection and/or implantation, it is possible that less-mature CMs might be better equipped to contend with the hostile environment of the infarcted myocardium.
Another major difficulty is that despite these methodological advances, generating patient-specific iPSC-derived CMs (iPSCCMs) still requires 2-3 months from biopsy to CMs, and may present a potential risk of teratoma formation due to residual pluripotent cells [41] . Consequently, direct reprogramming strategies are being explored. Proof-of-concept mouse studies show somatic cells can be directly converted to CMs [42] [43] [44] . Recently, direct reprogramming of human fibroblasts was also achieved [45] . However, current induced CM (iCM) protocols have low efficiencies compared with iPSC-CM protocols (5%-13% vs. 90%-95%) [16] . Also, iCMs are not fully characterized. Some reports suggest they are similar to ESC-CMs [46, 47] , whereas others report they are less mature than hiPSC-CMs [48] . Regardless, transdifferentiation could revolutionize regenerative medicine by eliminating the risk of teratomas, and by directly reprogramming fibroblasts in the postinfarct scar into functional myocardium in vivo.
CELL INJECTION
The most common cell replacement therapy is the direct injection of cell suspensions using catheters or open chest surgery [49] . Clinical trials to test safety and efficacy have been conducted for various adult stem cell and progenitor populations [16] , including bone marrow mesenchymal stem cells (MSCs), peripheral mononuclear cells (PMCs), and resident cardiac cells. Notably, these cell types have no intrinsic ability to produce large numbers of CMs. Rather, it is thought they secrete paracrine factors that act directly to induce beneficial effects or indirectly by altering gene expression in the surrounding myocardium [50] . In fact, most cardiac cell injection studies achieved beneficial effects without long-term cell persistence [50] . Examples of identified paracrine factors include vascular endothelial growth factor [51] , thymosin b4 [52] , and stromal-derived factor [53] . Recently, a secretome analysis of human bone marrow cells identified a novel cardioprotective and angiogenic paracrine factor, myeloidderived growth factor [54] .
Overall, these trials have shown varying degrees of clinical benefit [49] . A meta-analysis of 10 intracoronary cell injection trials using BMCs and PMCs showed modest but significant functional improvements in patients treated within 14 days of an acute MI [55] . In general, the clinical trial results to date have been moderate, which has spawned debates on what constitutes a clinically meaningful improvement and how success should be measured. While these debates continue, new clinical trials are being initiated. In a recent proof-of-principle clinical trial, single-cell, hESC-derived CPCs were embedded in a fibrin gel and implanted onto the epicardium of patients with severe heart failure by positioning the cell-fibrin mixture beneath the pericardial flap [56] . There are also ongoing efforts to gain approval for hPSC-CM clinical trials [16, 57] .
Improved outcomes from cell injection therapies may result from the combined delivery of cells and paracrine factors and/ or cell suspensions that contain multiple cell types (e.g., a CM source and endothelial cells [ECs] ) to promote vascularization [58] . To date, the single-pronged approach has yielded results below the benchmark of true regeneration. Conversely, a multipronged synergistic approach could promote engraftment and vascularization, and ultimately, functional improvements. ; and graft-host electrical coupling was reported in both rat [61] and guinea pig [62] (Fig.  1Aa , Ab) models. However, small animals have faster beat rates than humans (e.g., human CMs: 60-120 bpm; rodent: 350-600 bpm; guinea pig: 200-250 bpm [62] ), and although hESC-CMs can beat at 6 Hz (360 bpm) under electrical field stimulation [63] , prolonged (.2 weeks) conditioning at this rate may result in a pathological phenotype and cell death. Large-animal models, therefore, are considered more suitable for hPSC-CM integration studies because of the overlap in graft and host beat rates [6] . Limited integration was observed in pigs (55-120 bpm) transplanted with hESC-CMs [64] (Fig. 1Ac) ; and although integration was evident in a nonhuman primate model (100-130bpm), transient but serious arrhythmias were observed following cell application [6] (Fig. 1Ad) . These results may very well illustrate another important limitation of animal models-species-tospecies differences in ion channel expression [65] , which may hinder electrical coupling.
Alternatively, the moderate success of cell injection therapy could be attributed to the relative immaturity of the transplanted cells [6] . Electrical conduction and coupling (e.g., ion channel currents, densities, and kinetics [66] ), as well as contractile rate and force, are all developmentally regulated and distinctively different in hPSC-CMs and human adult CMs [67] . Long-term culture has induced some degree of maturation [66] , but extending the timeline from biopsy to implantation is not desirable, and the degree of maturation achieved by extended culture is insufficient. The injection of isolated cells also cannot provide the tissue-level connections and organization needed for immediate functionality. The ability of the graft to function upon implantation and/or its nearer resemblance to adult tissue are considered possible solutions to adverse remodeling and rapid host-graft integration.
CARDIAC PATCH
Cardiac patches have been investigated as a possible solution to cell injection challenges. Cell injection strategies have a maximal engraftment efficiency of 10% because of rapid wash out, ejection, and death of the injected cells [68, 69] . Cell requirements, therefore, are massive (e.g., 1 billion CMs for a sizable graft in a monkey) [6] . Cell retention and survival has been improved by injecting cells with hydrogels that rapidly gel in situ [69] . In vitro cultured cardiac patches provide even better delivery precision and retention of transplanted material. Through in vitro cultivation, the size, shape, and functional properties of cardiac patches can also be tailored; and bioactive peptides and growth factors (e.g., paracrine factors) can be released in a controlled and targeted manner.
Engineered cardiac tissues (ECTs) are designed to manipulate the cell microenvironment to facilitate cell assembly into functional tissues with adult-like morphological, functional, and mechanical properties. Various synthetic [poly(glycerol sebacate), polyglycolic acid, poly-L-lactic acid] and natural (alginate, collagen, chitosan, decellularized heart) biomaterials have been used as hydrogels and scaffolds [69, 70] ), and advances in microfabrication and nanotechnology have enabled the generation of highly anisotropic tissues [71] [72] [73] [74] . The majority of three-dimensional (3D) ECTs have used rat CMs [68, 70] ; however, human ECTs have recently emerged [67] . Improved structural and functional properties of 3D ECTs and enhanced survival in vivo have been demonstrated through strategic cocultures with fibroblasts (or MSCs [75] ) and CMs, likely because of the matrix deposition and paracrine signaling activity of the nonmyocytes [68] . Similarly, coculture with ECs in 3D ECTs has proved beneficial, demonstrating increased vascularization and CM proliferation, and host vasculature anastomosis [68, 75] . Several key maturation features have also been improved using ECT-based strategies (e.g., electrical field stimulation, mechanical stretching [cyclic, static or incremental] and topographical alignment cues [67] ).
Proof-of-concept studies demonstrated that patches of neonatal rat CMs implanted onto infarcted hearts of syngeneic rats could integrate with the host heart, induce functional improvements, and electrically couple without delay or evidence of arrhythmias [76] . The beneficial outcomes of cardiac patch therapy have been extensively demonstrated in small-animal models [75, 77, 78] and are currently being tested in large-animal models [58] .
An important obstacle to clinical application is the need for thicker cardiac patches. A recent study demonstrated transplanted tissue sections .400 mm thick have poor survival due to diffusion limitations [79] . The most effective method of producing thick ECTs will likely involve an embedded engineered vasculature that enables immediate and direct anastomosis with the host vasculature. As mentioned, coculture with ECs promotes vascularization of ECTs, but thick tissues will require a higher density of branched vessels than this strategy can provide, given the high metabolic activity of CMs. Various vascularization strategies have been investigated (e.g., chemically modifying scaffolds [80] , embedding microvessel fragments [80] , and 3D printing scaffolds with sacrificial molds that form vessel-like structures [81, 82] ).
One notable strategy to produce thicker tissues involves stacking layers of cardiac tissue. A scaffold-free approach was developed wherein cultured CM monolayers are released as intact cell sheets from a temperature-sensitive culture surface [83] , and ECT scaffolds were attached together by a series of loops and hooks, inspired by the mechanisms of Velcro (Velcro Industries, Manchester, NH, http://www.velcro.com) and plant burr attachment [84] . Either of these stacking methods suggests the possibility of integrating an engineered EC layer amid the CM layers, which could promote vascularization and enable thicker tissues to be formed.
IMPLANTATION LOCATION
It remains to be determined where cells or cardiac patches should be implanted for optimal therapeutic benefit. The ventricular wall is comprised of the epicardium, the outer epithelial muscle lining; the myocardium, the muscle tissue; and the endocardium, the inner endothelial muscle lining ( Fig. 2A) . Proponents of intramyocardial placement point to evidence of integration therein with cell injections, and, in a recent comparative study, better grafthost electrical integration was observed with intramyocardial delivery than epicardial placement [85] .
However, direct injection of a cell suspension into the myocardium (Fig. 2B) is inherently limited by the very small volume of free space available because of the high cell density in the myocardium (10 8 cells per cm 3 [86] ). This space becomes more restricted following injury such as MI when dead cells are replaced by a dense collagenous scar. Conversely, the epicardial surface can readily accommodate a cardiac patch of clinically relevant size (Fig.  2C) . Epicardial cardiac patch placement was found to induce functional improvement post-MI [58, 76] , and a recent clinical trial was also initiated wherein hESC-derived CPCs in a fibrin hydrogel were applied during open chest surgery onto the epicardium [56] . Moreover, the epicardium is considered a safe location for patch deployment relative to the endocardium, where the risk of embolization and thrombosis is high (Fig. 2) . A major criticism of epicardial placement is that epicardial cells are not CMs; thus, they can physically separate the graft and host myocardium and hinder electrical coupling. During development, epicardial-derived cells robustly support myocardial growth by providing progenitor cells and mitogens [87, 88] . Postnatally, epicardial cells migrate into the myocardium, especially after injury, to give rise to both ECs and smooth muscle cells of new blood vessels and possibly functional CMs [87, 88] . Given the beneficial role of the epicardium during development and following injury, the way forward may be to harness its power by introducing bioactive peptides into a cardiac patch to mobilize epicardial cells and eliminate the graft-host tissue barrier. For example, thymosin b4 promotes the migration of epicardial cells into the myocardium, and induces both coronary vascularization and CM survival [88] ; and follistatin-like 1 was shown to promote integration, limit fibrosis, and improve cardiac function, CM proliferation, and vascularization, when applied via an acellular epicardial patch, but not when it was transgenically overexpressed [87] . 
CONCLUSION
If we are to see a meaningful advancement in cardiac cell replacement therapy, a strategy that is suitable for cell delivery in a large number of patients is needed. The vast cell numbers required and the problems with long-term persistence and integration hamper cell injection therapy. Although it is possible that maturation could be induced in the context of single-cell suspensions by manipulating endogenous expression levels [89] [90] [91] of key proteins or treating cells with exogenous chemical signals (e.g., growth factors, hormones), these strategies typically induce a higher degree of maturation in the context of 3D ECTs. On the other hand, cardiac patch therapy requires open chest surgery, which excludes a large number of patients who would benefit from such therapy; the risk of a thrombotic event also could deter patients with thrombotic/embolic predispositions. Additionally, standardized protocols for ECT generation and maturation will be required before clinical translation is possible. Given the current state of the art, it seems most likely that a true regenerative therapy will come in the form of a thick, vascularized, adult-like, functional ECT and/or a patch that secretes bioactive molecules to mobilize epicardial cells, delivered by a minimally invasive method to the epicardial surface of the heart. There are obviously numerous challenges that need to be met before this can become a reality, but with the rapid advancements over the last decade, it is only a matter of time before the solutions are found. 
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